UK markets closed

MEI Pharma, Inc. (0JW9.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.2534-0.0285 (-10.11%)
At close: 05:01PM GMT
Full screen
Previous close0.2819
Open0.2552
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.2534 - 0.2598
52-week range0.2534 - 0.2598
Volume39,200
Avg. volumeN/A
Market cap180,653
Beta (5Y monthly)0.84
PE ratio (TTM)N/A
EPS (TTM)-0.5190
Earnings date08 Feb 2023 - 13 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    MEI Pharma Announces Adjournment of Annual Meeting of Stockholders

    SAN DIEGO, December 06, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been adjourned to January 5, 2023, at 9:00 a.m. Pacific Time. The record date for the adjourned annual meeting continues to be October 13, 2022.

  • Business Wire

    MEI Pharma Initiates Strategic Realignment

    SAN DIEGO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it plans to initiate a realignment of its clinical development efforts following the discontinuation of global development outside Japan of its PI3K delta inhibitor, zandelisib. As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib a

  • Business Wire

    MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

    SAN DIEGO & TOKYO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing glob